+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2025- Product Image
Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2025- Product Image
New

Oncolytic Virus Cancer Therapy Pipeline Analysis Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 5997636
Description Jump to:
According to the American Cancer Society, in 2024, over 600,000 individuals in the United States are expected to die from cancer. As a result, the emphasis on developing high-efficacy therapies for treatment is at its peak. With collaborations between biotech companies, research and academic institutions, oncolytic virus therapies are witnessing accelerated development and commercialization.

Report Coverage

The Oncolytic Virus Cancer Therapy Drug Pipeline Insight Report by the publisher gives comprehensive insights into oncolytic virus cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for oncolytic virus cancer therapy. The oncolytic virus cancer therapy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The oncolytic virus cancer therapy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with oncolytic virus cancer therapy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to oncolytic virus cancer therapy.

Oncolytic Virus Cancer Therapy Pipeline Outlook

Oncolytic virus cancer therapy involves the administration of a virus to attack the tumor cells in a cancer patient's body. These cancer cells infecting virus cells replicate at a fast pace and destroy tumor cells by opening their exterior and exposing the cell content to the immune system.

Only one oncolytic virus, T-VEC (talimogene laherparepvec) has been approved by the United States FDA for metastatic melanoma. Approved in 2015, T-VEC (Imlygic®) is a modified version of herpes simplex virus (HSV). It has been modified to infect cancer cells to produce GM-CSF (an immune-stimulating protein).

These viruses are designed in a way to target cancer cells by identifying their abnormalities such as mutations or differences on the cell surface of proteins. The study of oncolytic therapies is based on several virus types such as adenoviruses, herpes simplex viruses, poxviruses, and others. Each type of virus has a unique characteristic that influences its safety and efficacy against a distinct type of cancer cell. Several oncolytic virus cancer therapy drugs are currently under clinical trials.

The Oncolytic Virus Cancer Therapy Pipeline Report covers the pathophysiology and epidemiology, developing treatment, and the progress and future aspects of ongoing clinical trials in detail.

Oncolytic Virus Cancer Therapy Pipeline Therapeutic Assessment

This section of the report covers the analysis of oncolytic virus cancer therapies drug candidates on various segmentations such as:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Route of Administration

The oncolytic virus cancer therapy report assessment report covers 50+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others

Oncolytic Virus Cancer Therapy - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase I trials cover a major share of the total clinical trials conducted, with approximately 40 plus oncolytic virus cancer therapy emerging drugs undergoing clinical development.

Oncolytic Virus Cancer Therapy - Pipeline Assessment Segmentation, By Route of Administration

The route of administration categories covered under the oncolytic virus cancer therapy pipeline analysis include oral, parenteral, and others. The report provides a comparative analysis of the route of administration for each drug in various phases of clinical trials. According to analysis, the parenteral route holds a significant market share based on the route of administration.

Oncolytic Virus Cancer Therapy Clinical Trials Assessment - Competitive Dynamics

The report for the oncolytic virus cancer therapy pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed oncolytic virus cancer therapy clinical assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in oncolytic virus cancer therapy clinical trials:
  • Oncostar LLC
  • Lokon Pharma AB
  • Binhui Biopharmaceutical Co., Ltd.
  • Hangzhou Converd Co., Ltd.
  • Syneos Health, Inc.
  • Astellas Pharma Global Development, Inc.
  • Johnson & Johnson Enterprise Innovation Inc.

Oncolytic Virus Cancer Therapy - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs. It covers product description, trial ID, study type, drug class, mode of administration, and recruitment status of oncolytic virus cancer therapy clinical trial drugs.

CF33-hNIS

It is an oncolytic virus monotherapy candidate that is being investigated for gastrointestinal cancer treatment by a team of researchers at the Karmanos Cancer Center in Detroit, United States. CF33-hNIS has started demonstrating evidential efficacy against the condition.

R130

This oncolytic virus injection is being evaluated for advanced solid tumor treatment. Sponsored by Shanghai Yunying Medical Technology, this recombinant oncolytic herpes simplex virus type 1 (R130) is under investigation against breast cancer and pancreatic cancer.

LOAd703

An oncolytic adenovirus, LOAd703 is an oncolytic virus cancer therapy drug candidate. As a part of the study, it will be administered via intramural injections and will be added to standard-of-care treatment with gemcitabine and nab-paclitaxel.

OH2

Developed by making genetic alterations in the herpes simplex virus type 2 strain HG52, OH2 oncolytic cancer is under trials for locally advanced or metastatic bladder cancer. Currently evaluated in the BH-OH2-017 multicenter clinical trial, it will be delivered once every two weeks. However, the injection dosage will be reduced to once a month during the maintenance treatment period.

Reasons To Buy This Report

The Oncolytic Virus Cancer Therapy Drug Report provides a strategic overview of the latest and future landscape of treatments for oncolytic virus cancer therapy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within the oncolytic virus cancer therapy pipeline insights.

Key Questions Answered in the Oncolytic Virus Cancer Therapy - Pipeline Assessment Report

  • What is the current landscape of oncolytic virus cancer therapy drugs?
  • How many companies are developing oncolytic virus cancer therapies?
  • How many phase I and phase II drugs are currently present in oncolytic virus cancer therapies?
  • Which companies/institutions are leading the oncolytic virus cancer therapy development?
  • What is the efficacy and safety profiles of oncolytic virus cancer therapy?
  • What are the opportunities and challenges present in the oncolytic virus cancer therapy landscape?
  • Which company is conducting major trials for oncolytic virus cancer therapy?
  • What are the geographies covered for clinical trials in oncolytic virus cancer therapy?
  • What are emerging trends in oncolytic virus cancer therapy clinical trials?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Oncolytic Virus Cancer Therapy
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Oncolytic Virus Cancer Therapy
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Oncolytic Virus Cancer Therapy: Epidemiology Snapshot
5.1 Oncolytic Virus Cancer Therapy Incidence by Key Markets
5.2 Oncolytic Virus Cancer Therapy- Patients Seeking Treatment in Key Markets
6 Oncolytic Virus Cancer Therapy: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Oncolytic Virus Cancer Therapy: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Oncolytic Virus Cancer Therapy, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Oncolytic Virus Cancer Therapy Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Oncolytic Virus Cancer Therapy Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 OH2
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Recombinant Human Adenovirus Type 5 injection
10.2.3 Pexastimogene Devacirepvec (Pexa Vec)
10.2.4 Sorafenib
10.2.5 Other Drug
11 Oncolytic Virus Cancer Therapy Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Gemcitabine
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Oncorine (H101)
11.2.3 H101
11.2.4 ADV/HSV-tk
11.2.5 Other Drugs
12 Oncolytic Virus Cancer Therapy Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Double Recombinant Vaccinia Virus VV-GMCSF-Lact
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Ad-TD-nsIL12
12.2.3 Oncolytic Virus SDJ001
12.2.4 Other Drugs
13 Oncolytic Virus Cancer Therapy Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Recombinant oncolytic herpes simplex virus type 1 (R130)
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Recombinant L-IFN adenovirus
13.2.3 OVV-01
13.2.4 Pelareorep
13.2.5 Other Drugs
14 Oncolytic Virus Cancer Therapy, Key Drug Pipeline Companies
14.1 Oncostar LLC
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Lokon Pharma AB
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Binhui Biopharmaceutical Co., Ltd.
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Hangzhou Converd Co., Ltd.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Syneos Health, Inc.
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Astellas Pharma Global Development, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Johnson & Johnson Enterprise Innovation Inc.
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

Related Topics

Related Reports

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025 - Product Image

Oncolytic Virus Cancer Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • 280 Pages
  • Global
From
Oncolytic Virus Therapy - Global Strategic Business Report - Product Image

Oncolytic Virus Therapy - Global Strategic Business Report

  • Report
  • 483 Pages
  • Global
From
Oncolytic Virus Immunotherapy - Global Strategic Business Report - Product Image

Oncolytic Virus Immunotherapy - Global Strategic Business Report

  • Report
  • 383 Pages
  • Global
From
Oncolytic Virus Therapy Market Report 2025 - Product Image

Oncolytic Virus Therapy Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034) - Product Image

Oncolytic Virus Cancer Therapy Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.